Dynavax Technologies News and Activities

Presence

Dynavax Technologies develops and supplies vaccines and immune-focused products. Its main offerings include hepatitis prevention vaccines and vaccine adjuvant technology for healthcare providers, governments, and pharmaceutical companies.

Dynavax Technologies products and services overview:

Vaccines
Vaccine adjuvants
Immunology products
Biotech research services

Revenue: ~$270 million

Employees: 300

Headquarters: Emeryville, United States (USA)

Dynavax Technologies is one of the...

Dynavax Technologies is a company listed under the stock ticker DVAX (US).

Acquisition, funding and merger involving Dynavax Technologies.

Sanofi has acquired Dynavax Technologies (posted on February 23 2026).
Sanofi has announced the acquisition of Dynavax Technologies (posted on December 29 2025).

Executives

View the org chart displaying its 30 main executives

Most searched biographies at Dynavax Technologies

Popular executive movements at Dynavax Technologies

Robert Janssen, Chief Medical Officer and Senior Vice President, Clinical Development, will leave the company on Mar. 2, 2026 (posted on October 17 2025).

Create your alert
to follow the executive moves at Dynavax Technologies.

Biotechnology

Dynavax Technologies has 2,415 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).
Boundless Bio will change its company name to Serapha Bio on Dec 31, 2026. (posted on June 23 2026).